Bioadaptives, Inc. (BDPT) Cost of Revenue (2016 - 2026)

Bioadaptives (BDPT) posted Cost of Revenue of $1401.0 for Q1 2026, down 50.74% sequentially from $2844.0 in Q4 2025.

Bioadaptives, Inc. (BDPT) Cost of Revenue (2016 - 2026) Analysis & Trends

Bioadaptives has reported Cost of Revenue for 9 years, with the latest figure at $1401.0 in Q1 2026.

Quarterly Cost of Revenue changed N/A year-over-year to $1401.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7182.0 (up 2819.51% YoY) and the FY2025 annual result came in at $5781.0, down 33.08% from the prior year.
Cost of Revenue slipped to $1401.0 in Q1 2026 per BDPT's latest filing, from $2844.0 in the prior quarter.
Over five years, Cost of Revenue peaked at $10999.0 in Q3 2023 and troughed at $246.0 in Q2 2024.
A 5-year average of $3115.5 and a median of $2162.5 in 2022 frame the typical range for Cost of Revenue.
The sharpest annual moves came in 2024 and 2025: Cost of Revenue sank 71.02% in 2024, then soared 776.42% in 2025.
Over 5 years, Cost of Revenue stood at $2954.0 in 2022, then jumped by 52.4% to $4502.0 in 2023, then plunged by 94.54% to $246.0 in 2024, then jumped by 1056.1% to $2844.0 in 2025, then sank by 50.74% to $1401.0 in 2026.
According to Business Quant data, Cost of Revenue over the past three periods registered $1401.0, $2844.0, and $781.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Download Data